13G Filing: Tappan Street Partners and Peregrine Pharmaceuticals Inc (PPHM)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under
the Securities Exchange Act of 1934*

(Amendment
No. 1)

Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.

The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).

*
Tappan Street Partners LLC is the investment manager of the Tappan Street Partners Fund L.P. (the “Fund”) and the
Tappan Street Partners Ideas Fund L.P. (the “Ideas Fund” and together with the Fund, the “Funds”) in which
such shares referred to above are held. As a result, Tappan Street Partners LLC possesses the power to vote and dispose or direct
the disposition of all the shares owned by the Funds. Thus, Tappan Street Partners LLC may be deemed to beneficially own a total
of 2,231,577 shares.

†Based
on a total of 45,069,188 Shares outstanding of the Issuer as of July 11, 2017, as set forth in the Issuer’s most recent
Form 10-K, filed July 14, 2017.

†Based
on a total of 45,069,188 Shares outstanding of the Issuer as of July 11, 2017, as set forth in the Issuer’s most recent
Form 10-K, filed July 14, 2017.

†Based
on a total of 45,069,188 Shares outstanding of the Issuer as of July 11, 2017, as set forth in the Issuer’s most recent
Form 10-K, filed July 14, 2017.

*
Mr. Phatak is the managing member of Tappan Street Partners LLC. As a result, Mr. Phatak possesses the power to vote and dispose
or direct the disposition of all the shares beneficially owned by Tappan Street Partners LLC as investment manager to the Funds.
Mr. Phatak disclaims beneficial ownership of any of the shares held by the Funds.

†Based
on a total of 45,069,188 Shares outstanding of the Issuer as of July 11, 2017, as set forth in the Issuer’s most recent
Form 10-K, filed July 14, 2017.

*Mr.
Phatak is the managing member of Tappan Street Partners LLC. As a result, Mr. Phatak possesses the power to vote and dispose or
direct the disposition of all the shares beneficially owned by Tappan Street Partners LLC as investment manager to the Funds.
Mr. Phatak disclaims beneficial ownership of any of the shares held by the Funds.

By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.

After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.

EXHIBIT
A

Joint
Filing Agreement

The
Undersigned agree that the statements on Schedule 13G with respect to the common stock of Peregrine Pharmaceuticals, Inc. dated
as of August ___, 2017, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them
pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.